SLC5A2 and acute kidney injury: These limitations include a potential bias in the indication of SGLT2 inhibitors (propensity helps but does not eliminate the risk), the possible prescription of an SGLT2 inhibitor outside the capture by the VA system, and the necessity for the patient to have survived the first year post-AKI (survivor bias10).